3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorderRecruitingPhase 32026-09-04NCT07517263
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorderActive, not recruitingPhase 32026-09-04NCT05739383
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular EventsInfarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, coronary artery disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorderRecruitingPhase 32026-08-21NCT07136012